The ghrelin-obestatin system in health and disease


Cite item

Full Text

Abstract

The role of the ghrelin-obestatin system in health and disease is multifaceted and new ample evidence has been recently accumulated. Ghrelin was discovered much earlier than obestatin so the biological, physiological and pathophysiological, pharmacological aspects of its activity could be studied far better than obestatin. There is no question that these hormones are not antagonists and they are a uniform system. However, there is a need for further studies of the role of this system in the body's vital functions in health and disease. The paper analyzes the accumulated information on the ghrelin-obestatin system in health and disease, assesses the possibility of their use in clinical practice, and pays attention to the unsolved problems to be explored and solved.

Full Text

Система грелин-обестатин в норме и при патологии. - Аннотация. Роль системы грелин-обестатин в норме и патологи многогранна, и за последние годы об этом накоплено много новых фактов. Грелин открыт значительно раньше обестатина, поэтому биологические, физиологические и патофизиологические, фармакологические аспекты его деятельности успели изучить значительно лучше. В настоящее время нет сомнений, что эти гормоны не являются антагонистами, а представляют единую систему. Однако необходимы дальнейшие исследования роли этой системы в жизнедеятельности организма в норме и патологии. В статье проанализированы накопленные сведения о системе грелин-обестатин в норме и при патологии, оценена возможность их применения в клинической практике, обращено внимание на проблемы, которые не решены, но которые предстоит изучать и решать.
×

About the authors

I V TereShchenko

Email: i_v_t@bk.ru

P E Kaiushev

References

  1. Kojima M., Hosoda H., Date Y. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
  2. Zhang J.V., Ren P.-G., Avsian-Kretchmer O. et al. Medicine: obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310 (5750): 996-999.
  3. Hassouna R., Zizzari P., Tolle V. The ghrelin/obestatin balance in the physiological and pathological control of growth hormone secretion, body composition and food intake. J Neuroendocrinol 2010; 22 (7): 793-804.
  4. Zizzari P., Hassouna R., Grouselle D. et al. Physiological roles of preproghrelin-derived peptides in GH secretion and feeding. Peptides 2011; 32 (11): 2274-2282.
  5. Bresciani E., Rapetti D., Donà F. et al. Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. Journal of Endocrinological Investigation. 2006; 29 (8): 16-18.
  6. Epelbaum J., Bedjaoui N., Dardennes R. et al. Role of the ghrelin/obestatin balance in the regulation of neuroendocrine circuits controlling body composition and energy homeostasis. Mol Cell Endocrinol 2010; 314 (2): 244-247.
  7. De Smet B., Thijs T., Peeters T.L., Depoortere I. Effect of peripheral obestatin on gastric emptying and intestinal contractility in rodents. Neurogastroenterol Motil 2007; 19 (3): 211-217.
  8. Tsolakis A.V., Grimelius L., Stridsberg M. et al. Obestatin/ghrelin cells in normal mucosa and endocrine tumours of the stomach. Eur J Endocrinol 2009; 160 (6): 941-949.
  9. De Smet B., Thijs T., Peeters T.L., Depoortere I. Effect of peripheral obestatin on gastric emptying and intestinal contractility in rodents. Neurogastroenterol Motil 2007; 19 (3): 211-217.
  10. Lippl F., Erdmann J., Lichter N. et al. Relation of plasma obestatin levels to BMI, gender, age and insulin. Hormone Metabol Res 2008; 40 (11): 806-812.
  11. Zhang J.V., Jahr H., Luo C.-W. et al. Obestatin induction of early-response gene expression in gastrointestinal and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Molr Endocrinol 2008; 22 (6): 1464-1475.
  12. Dong X.Y., He J.M., Tang S.Q. et al. Is GPR39 the natural receptor of obestatin? Peptides 2009; 30 (2): 431-438.
  13. Holst B., Egerod K.L., Schild E. et al. GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 2007; 148 (1): 13-20.
  14. Scrima M., Campiglia P., Esposito C. et al. Obestatin conformational features: a strategy to unveil obestatin's biological role? Biochem Biophys Res Commun 2007; 363 (3): 500-505.
  15. Gourcerol G., St-Pierre D.H., Taché Y. Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)? Regul Pept 2007; 141: 1-7.
  16. Van Dijck A., Van Dam D., Vergote V. et al. Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. Regul Pept 2009; 156: 77-82.
  17. Beasley J.M., Ange B.A., Anderson C.A.M. et al. Characteristics associated with fasting appetite hormones (obestatin, Ghrelin, and Leptin). Obesity 2009; 17 (2): 349-354.
  18. Kapica M., Zabielska M., Puzio I. al. Obestatin stimulates the secretion of pancreatic juice enzymes through a vagal pathway in anaesthetized rats - preliminary RESULTS. J Physiol Pharmacol 2007; 58 Suppl 3: 123-130.
  19. Gronberg M., Tsolakis A.V., Magnusson L. et al. Distribution of obestatin and ghrelin in human tissues: immunoreactive cells in the gastrointestinal tract, pancreas, and mammary glands. J Histochem Cytochem 2008; 56: 793-801.
  20. Benedix F., Westphal S., Patschke R. et al. Comparison of serum and salivary ghrelin in healthy adults, morbidly obese, and patients with metastatic carcinoma. Obes Surg 2011; 21 (8): 1265-1271.
  21. Ozbay Y., Aydin S., Dagli A.F. et al. Obestatin is present in saliva: alterations in obestatin and ghrelin levels of saliva and serum in ischemic heart disease. BMB Rep 2008; 41 (1): 55-61.
  22. Volante M., Rosas R., Ceppi P. et al. Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. J Pathol 2009; 218 (4): 458-466.
  23. Hassouna R., Zizzari P., Tolle V. The ghrelin/obestatin balance in the physiological and pathological control of growth hormone secretion, body composition and food intake. J Neuroendocrinol 2010; 22 (7): 793-804.
  24. Zhang N., Yuan C., Li Z. et al. Meta-analysis of the relationship between obestatin and ghrelin levels and the ghrelin/obestatin ratio with respect to obesity. Am J Med Sci 2011; 341 (1): 48-55.
  25. Guo Z.-F., Zheng X., Qin Y.-W. et al. Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol Metabol 2007; 92 (5): 1875-1880.
  26. Gurriarán-Rodríguez U., Al-Massadi O., Roca-Rivada A. et al. Obestatin as a regulator of adipocyte metabolism and adipogenesis. J Cell Mol Med 2011; 15 (9): 1927-1940.
  27. Qi X., Li L., Yang G. et al. Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007; 66 (4): 593-597.
  28. Harsch I.A., Koebnick C., Tasi A.M. et al. Ghrelin and obestatin levels in type 2 diabetic patients with and without delayed gastric emptying. Dig Dis Sci 2009; 54 (10): 2161-2166.
  29. Sedlácková D., Dostálová I., Hainer V. et al. Simultaneous decrease of plasma obestatin and ghrelin levels after a high-carbohydrate breakfast in healthy women. Physiol Res 2008; 57: 29-37.
  30. Dezaki K., Sone H., Yada T. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 2008; 118 (2): 239-249.
  31. Dezaki K. Ghrelin function in insulin release and glucose metabolism. Endocr Dev 2013; 25:135-143.
  32. Delhanty P.J., van der Lely A.J. Ghrelin and glucose homeostasis. Peptides 2011; 32 (11): 2309-2318.
  33. Кириенкова Е.В., Литвинова Л.С., Селедцов В.И. и др. Метаболические и сердечно-сосудистые эффекты грелина. Ожирение и метаболизм 2012; 1: 3-7.
  34. Barazzoni R., Zanetti M., Ferreira C. et al. Relationship between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3935-3940.
  35. Pagotto U., Gambineri A., Vicennati V. et al. Plasma ghrelin, obesity and polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 2002; 87: 5625-5629.
  36. Dezaki K., Yada T. Islet Β-cell ghrelin signaling for inhibition of insulin secretion. Methods Enzymol 2012; 514: 317-331.
  37. Sjölund K., Ekman R., Wierup N. Covariation of plasma ghrelin and motilin in irritable bowel syndrome. Peptides 2010; 31 (6): 1109-1112.
  38. Karmiris K., Koutroubakis I.E., Kouroumalis E.A. Leptin, adiponectin, resistin, and ghrelin - implications for inflammatory bowel disease. Mol Nutr Food Res 2008; 52 (8): 855-866.
  39. Alexandridis E., Zisimopoulos A., Liratzopoulos N. et al. Obestatin/ghrelin ratio: a new activity index in inflammatory bowel diseases. Inflamm Bowel Dis 2009; 15 (10): 1557-1561.
  40. Volante M., Rosas R., Ceppi P. et al. Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. J Pathol 2009; 218 (4): 458-466.
  41. Walter T., Chardon L., Hervieu V. et al. Major hyperghrelinemia in advanced well differentiated neuroendocrine carcinomas: report of three cases. Eur J Endocrinol 2009; 161: 639-645.
  42. Beberashvili I., Sinuani I., Azar A. et al. Low Serum Concentration of Obestatin as a Predictor of Mortality in Maintenance Hemodialysis Patients. Biomed Res Int 2013; 2013: 796586. Published online 2013 September 12. doi: 10.1155/2013/796586 www.ncbi.nlm.nih.gov/pmc/articles/PMC3786512/
  43. Granata R., Isgaard J., Alloatti G., Ghigo E. Cardiovascular actions of the Ghrelin gene-derived peptides and growth hormone-releasing hormone. Experl Biol Med 2011; 236 (5): 505-514.
  44. Aygen B., Dogukan A., Dursun F.E. et al. Ghrelin and obestatin levels in end-stage renal disease. J Intern Med Res 2009; 37 (3): 757-765.
  45. Mafra D., Guebre-Egziabher F., Cleaud C. et al. Obestatin and ghrelin interplay in hemodialysis patients. Nutrition 2010; 26 (11-12): 1100-1104.
  46. Alloatti G., Arnoletti E., Bassino E. et al. Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. Am J Physiol 2010; 299 (2): 470-481.
  47. Estep M., Abawi M., Jarrar M. et al. Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes Surg 2011; 21 (11): 1750-1757.
  48. Mendes-Sanches N., Ponciano- Rodrigues G., Bermegjo-Martines L. et al. Low serum levels of ghrelin are assosiated with gallstone disease. World J Gastroenterol 2006; 12 (19): 3096-3100.
  49. Al Massadi O., Tschöp M.H., Tong J. Ghrelin acylation and metabolic control. Peptides 2011; 32 (11): 2301-2308.
  50. Nagava N., Moriya J., Yasumura Y. et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110 (24): 3674-3679.
  51. Mizia-Stec K., Zahorska-Markiewicz B., Olszanecka-Glinlanowicz M. et al. Ghrelin as a potential blood pressure reducing factor in obese women during weight loss treatment. Endokrynologia Polska 2008; 59 (3): 207-211.
  52. Mano-Otagirl A.,Ohata N., Iwasaki-Sekino A., Nemoto T. et al. Ghrelin suppresses noradrenaline release in the brown adipose tissue of rats. J. Endocrinology. 2009; 201 (3): 341-349.
  53. Soeki T., Kishimoto I.,Schwenke D. et al. Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rets with myocardial infarction. Am J Physiol 2008; 294 (1): 426-432.
  54. Agnew A.J., Robinson E., McVicar C.M. et al. The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling. Br J Pharmacol 2012; 166 (1): 327-338.
  55. Li Z.-F., Song S.-W., Qin Y.-W. et al. Bolus intravenous injection of obestatin does not change blood pressure level of spontaneously hypertensive rat. Peptides 2009; 30 (10): 1928-1930.
  56. Li Z.-F., Guo Z.-F., Cao J. et al. Plasma ghrelin and obestatin levels are increased in spontaneously hypertensive rats. Peptides 2010; 31 (2): 297-300.
  57. Kellokoski E., Kunnari A., Jokela M. et al. Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding. Metabolism 2009; 58 (11): 1572-1580.
  58. Lacquaniti A., Bolignano D., Donato V. et al. Obestatin: a new element for mineral metabolism and inflammation in patients on hemodialysis. Kidney Blood Pressure Res 2011; 34 (2): 104-110.
  59. Ogiso K., Asakawa A., Amitani H., Inui A. Ghrelin and anorexia nervosa: a psychosomatic perspective. Nutrition 2011; 27 (10): 988-993.
  60. Tschop M., Wawarta R., Riepl R.L. et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001; 24: 19-21.
  61. Парфенов А.И. Грелин и пептид YY - регуляторы аппетита и количества потребляемой пищи. Перспективы лечения кахексии и ожирения. Тер арх 2005; 2: 92-94.
  62. Van der Lely A.J., Tschop M., Heiman M.L., Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25 (3): 426-457.
  63. Reinehr T., de Sousa G., Roth C. Obesity and ghrelin levels in obese children and adolescents before and after reduction of overweight. Clin Endocrinol (Oxf) 2008; 68 (2): 304-310.
  64. Zou C.C., Liang L., Wang C.L. et al. The change in ghrelin and obestatin levels in obese children after weight reduction. Acta Рaediatr 2009; 98: 159-165.
  65. King N.A., Gibbons C.H., Martins C. Ghrelin and Obestatin Concentrations during Puberty: Relationships with Adiposity, Nutrition and Physical Activity. Med Sport Sci 2010; 55: 69-81.
  66. Gahete M.D., Córdoba-Chacón J., Kineman R.D. et al. Role of ghrelin system in neuroprotection fnd cognitive functions: implications in Alzheimer`s disease. Peptides 2011; 32 (11): 2225-2228.
  67. Ersahin M., Ozsavci D., Sener A. et al. Obestatin alleviates subarachnoid haemorrhage - induced oxidative ingury in rats via its antiapoptotic and antioxidant effects. Brain Inj 2013; 27 (10): 1181-1189.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies